Biomolecular Engineering Research Institute (BERI), Japan O6-methylguanine-DNA methyltransferase (MGMT) repairs the cytotoxic and mutagenic O6-alkylguanine produced by alkylating agents such as chemotherapeutic agents and mutagens. Recent studies have shown that in a subset of tumors, MGMT expression is inversely linked to hypermethylation of the CpG island in the promoter region; however, how the epigenetic silencing mechanism works, as it relates to hypermethylation, was still unclear. To understand the mechanism, we examined the detailed methylation status of the whole island with bisulfitesequencing in 19 MGMT non-expressed cancer cell lines. We found two highly methylated regions in the island. One was upstream of exon 1, including minimal promoter, and the other was downstream, including enhancer. Reporter gene assay showed that methylation of both the upstream and downstream regions suppressed luciferase activity drastically. Chromatin immunoprecipitation assay revealed that histone H3 lysine 9 was hypermethylated throughout the island in the MGMT negative line, whereas acetylation on H3 and H4 and methylation on H3 lysine 4 were at significantly high levels outside the minimal promoter in the MGMT-expressed line. Furthermore, MeCP2 preferentially bound to the CpG-methylated island in the MGMT negative line. Given these results, we propose a model for gene silencing of MGMT that is dependent on the epigenetic state in cancer.
Introduction
Alkylation of DNA at the O6 position of guanine leads to induction of mutations and cancers. Once O6-methylguanine (O6mG) is formed, it can pair with thymine during DNA replication, resulting in conversion of guanine-cytosine to adenine-thymine pairs. O6mG DNA methyltransferase (MGMT) repairs such a mutagenic adduct of O6mG. It catalyses transfer of the methyl group from O6mG to the cysteine residue of its own molecule, thereby repairing the DNA lesions in a single-step reaction (Olsson and Lindahl, 1980; Pegg et al., 1983) . MGMT is expressed in all normal human and mouse cells as a housekeeping gene. MGMTdeficient mice are hypersensitive to alkylating agents, leading to tumorigenesis or death (Becker et al., 1996; Sakumi et al., 1997) . Mice deficient in both MGMT and the mismatch repair protein MLH1 acquired tolerance to alkylating agents with increased survival rate and higher tumor frequency (Kawate et al., 1998) . In a subset of human primary tumors and tumor cell lines, MGMT is not expressed (Esteller et al., 1999) . These MGMT-negative tumors frequently have G to A transition mutations in K-ras and p53 (Esteller et al., 2000 (Esteller et al., , 2001 Whitehall et al., 2001) .
The MGMT gene has a TATA-less, CAT-less promoter containing a CpG island. The promoter with maximal activity lies 5 0 of the gene from À953 to þ 202 bp (transcription initiation site as þ 1), and consists of minimal promoter (À69 to þ 19) (Harris et al., 1991) , enhancer ( þ 143 to þ 202) (Harris et al., 1994) , to which MGMT enhancer-binding protein (MEBP) binds (Chen et al., 1997) , and several transcription factor-binding sites, such as SP1 and AP1 ( Figure 1a ). It has been reported that aberrant methylation of cytosine of CpG dinucleotides in the Promoter with maximal activity (BamHI to SstI, À953 to þ 202), minimal promoter (SmaI to XbaI, À69 to þ 19), and enhancer (FspI to SstI, þ 143 to þ 202) are indicated by arrows. SP1 sites are open boxes. The CpG island (À552 to þ 289) including 97 CpG sites, which is numbered from 5 0 to 3 0 , and an outline of CpG density are indicated by a gray box and vertical bars, respectively. The regions used for luciferase reporter assay -UHMR (PstI to XbaI, À570 to þ 19) and DHMR (XbaI to XhoI, þ 19 to þ 224) -are shown. 5 0 UHMR (PstI to FspI, À570 to À145) and 3 0 UHMR (FspI to XbaI, À145 to þ 19) are also shown. PCR regions for bisulfite-sequencing and ChIP assay are shown. CpG numbers covered by each ChIP-PCR product are in parentheses. (b) Detailed methylation status of the whole CpG island in MGMT( þ ) and MGMT(À) cell lines. Each circle graph represents each numbered CpG site and the percentage of methylated clones (number of methylated clones/10 analysed clones Â 100). CpGs included in minimal promoter and enhancer are shown in shaded boxes. A549 and LU65 with asterisks were used for ChIP assay DNA methylation and histone modifications at MGMT gene T Nakagawachi et al promoter region causes silencing of several tumor suppressor and DNA repair genes . The silencing of MGMT is also related to methylation of the 5 0 flanking region of the gene (von Wronski et al., 1992; Costello et al., 1994a; Danam et al., 1999; Herfarth et al., 1999) . Methyl-CpG binding (MBD) proteins, such as MeCP2 and MBD2, bind to the aberrant methylated sequences and recruit histone deacetylase complex, leading to alteration of chromatin configuration, to prevent binding of the transcription factors Mukai and Sekiguchi, 2002) . The importance of post-transcriptional histone modifications in epigenetic gene regulation, such as acetylation and methylation at amino-termini, has been emerging from recent studies (Jenuwein and Allis, 2001; Heard et al., 2001; Xin et al., 2001; Boggs et al., 2002; Peters et al., 2002) . It has also been reported that methylation of lysine 9 on histone H3 was associated with DNA hypermethylation of promoter and transcriptional silencing of tumor suppressor and DNA repair genes in cancer (Fahrner et al., 2002; Nguyen et al., 2002; Kondo et al., 2003) . However, the epigenetic mechanism of MGMT silencing still needed to be understood.
Here, we describe the detailed DNA methylation status of the whole CpG island, the effect of CpG island hypermethylation, and the histone modification status and binding of MBD proteins in MGMT expressed and repressed cancer cell lines. Based on our data, in conjunction with previous work, we propose a silencing mechanism of MGMT in cancer.
Results

MGMT expression and methylation status of CpG island in cancer cell lines
We screened a total of 131 human cancer cell lines derived from various tissues by RT-PCR, and found that the MGMT gene was not expressed in 19 lines (MGMT(À)) (14. 5%) (data not shown). Six out of 112 were selected as representative of MGMT expressed lines (MGMT( þ )). The expression level in these lines was confirmed by quantitative real-time RT-PCR normalized with expression of b-actin (Table 1) . Almost all MGMT(À) lines showed a reduction of less than 2% relative to normal lymphoblastoid cells as a standard, while in MGMT( þ ) lines, the expression level was 60-1398%. Thus, we used these lines to investigate DNA methylation of the CpG island in the promoter region.
We examined the methylation status of the CpG island containing minimal promoter and enhancer by bisulfite-sequencing ( Figure 1a) . Figure 1b shows the methylation status of a total of 97 CpG dinucleotides in the island of each line. The sequence in MGMT( þ ) lines was apparently hypomethylated, whereas that of the MGMT(À) lines was heavily methylated. A few lines, such as SaOS2 and YES3, showed hypomethylation. The methylation frequency was calculated at each CpG site in the MGMT( þ ) and MGMT(À) lines (data not shown). In MGMT( þ ) lines, methylation frequencies were basically null, although the first few CpGs were methylated. Otherwise, in MGMT(À) lines, we found two highly methylated regions in the CpG island, an upstream highly methylated region (UHMR) and a downstream highly methylated region (DHMR) ( Figure  1a and b). UHMR was upstream of the transcription initiation site, including a minimal promoter, and DHMR was downstream of exon 1, including an enhancer. The 5 0 portion of UHMR (5 0 UHMR), including the first one-third of the CpGs in the island (CpG1 to approximately CpG40), was highly methylated. After that, methylation status gradually decreased toward exon 1 via minimal promoter (3 0 UHMR). The CpGs in 5 0 UHMR were actually hypermethylated in all cell lines except SaoS2 and YES3. As to the methylation status of 3 0 UHMR, spanning approximately CpG40 to CpG73 and including minimal promoter, cell lines were divided into two groups: hypermethylated and hypomethylated. The hypermethylated group comprised nine out of 19 MGMT(À) lines, namely LU65, SW620, SW48, KSE140, KYSE510, HeLaTG, U251, HeLaMR, and 5637. The hypomethylated group comprised eight, including TE9, MDA-MB-435S, YES1, DBTRG-O5MG, LK2, HO-1-u-1, FRO, and SCCH26. DHMR was generally hypermethylated, especially the enhancer spanning CpG85 to CpG90, which was the most heavily methylated region in the island (Figure 1a and b) . 
Methylation of both the upstream and downstream regions suppresses gene transcription
To assess whether promoter hypermethylation causes transcriptional silencing of MGMT, we performed a functional analysis of promoter activity using a dual luciferase assay. It has been previously reported that methylation of the luciferase gene itself or methylation of the entire vector sequences, except the inserted promoter fragment, significantly reduced luciferase activity (Hsieh, 1997; Irvine et al., 2002; Satoh et al., 2003) . Thus, we made reporter constructs in which the inserted fragment was solely methylated and other sequences were not, to exclude the possible effect of ectopic methylation ( Figure 2 ). Considerable luciferase activity was detected in HeLa cells transfected with construct A harboring unmethylated CpG island, compared with mock vector, construct F (Figure 2 ). The activity of construct B harboring the fully methylated island was significantly reduced, to the same extent as the mock (99.8% reduction). Next, we used other constructs, such as C, D, and E, to investigate the methylation effect of each region -UHMR and DHMR -of the island. Considerable activity was also detected in cells transfected with construct C, made by ligation of unmethylated UHMR and DHMR; however, the activity of construct D, with only methylated UHMR, showed approximately 90% reduction compared with construct C. Construct E, with only methylated DHMR, showed 99.2% reduction, the same as the mock. Construct E had greater repression activity than construct C. Luciferase assay results indicated that the hypermethylation of the CpG island in MGMT promoter was sufficient for the suppression of gene transcription. Hypermethylation of either UHMR or DHMR was able to repress the transcription significantly. It was intriguing that the suppression activity of DHMR hypermethylation was the same as that of full methylation of the entire CpG island.
Characterization of anti-histone H3 dimethyl K9 monoclonal antibody 5.1.1
Since we could not obtain reproducible results from chromatin immunoprecipitation (ChIP) assay using a commercially available anti-dimethylated histone H3K9 antibody, we developed a monoclonal antibody against the histone H3 dimethyl K9 (H3meK9) using H3-m2K9 Figure 2 Luciferase reporter gene assay. The vector constructs are shown on the left. White and black boxes indicate unmethylated and fully methylated insert fragments, respectively. In all constructs, the luciferase gene itself and other vector sequences were not methylated at all. MluI was an artificial site generated for cloning into PBV. Construct C was used to confirm that a ligation step at XbaI did not influence luciferase activity. Relative luciferase activity of each construct is shown on the right. All experiments were repeated three times independently.
peptide. Three independent lines of evidence testify to the specificity of the H3meK9 antibody 5.1.1. First, this antibody recognized GST-H3 (1-57) in vitro methylated by recombinant GST-G9a-C (Figure 3a , right lane). Importantly, this antibody could not recognize a bacterially produced recombinant, unmethylated H3 (Figure 3a, left lane) . Second, the antibody selectively recognized histone H3 in acid-extracted histones and in immunoprecipitates with the antibody prepared from HeLa cells (Figure 3b) . Last, our antibody selectively recognized H3-m2K9 peptide on the BIAcore system, whereas three other peptides (H3-m2K4, H3-m2K27, and H4-m2K20) did not bind the antibody (Figure 3c ). Thus, we used this antibody for ChIP assay.
Difference of histone modification status between MGMT expressed and nonexpressed cell lines
To investigate histone modifications at the CpG island between MGMT expressed and non-expressed cells, we performed ChIP assay on two cell lines, A459 and LU65. A549 derived from lung cancer showed a mostly unmethylated CpG island and a high level of expression of MGMT, whereas LU65, also derived from lung cancer, was one of the most heavily methylated cell lines, in which MGMT expression was undetectable ( Figure 1b , Table 1 ). Three primer sets for ChIP-PCR were designed to amplify different regions -R1, R2, and R3 -that covered most of the 5 0 region of the CpG island in 5 0 UHMR, minimal promoter in 3 0 UHMR, and enhancer in DHMR, respectively (Figures 1a and 4a ). H3meK9, a marker of condensed and inactive chromatin, was significantly found in LU65 rather than in A549 at all three regions, indicating condensed chromatin throughout the island, with concomitant gene silencing. Acetylation of lysine residues on histone H3 and H4 (H3Ac and H4Ac), associated with open chromatin and active transcription, was apparently higher in A549 than in LU65 at R1 and R3 (Figure 4b and c) . At R2, however, there was no significant difference in H3Ac and H4Ac between the two lines. Methylation of lysine 4 on H3 (H3meK4), which is also associated with open chromatin and active transcription, showed the same pattern as the acetylation.
We also investigated the histone modification status at 1.9 kb upstream (R4) and 3.3 kb downstream (R5) of transcription initiation site. As shown in Figure 4d , the modifications were low, and no statistical difference between the two cell lines was found. This result suggested that alteration of histone modification did not extend upstream and downstream of the CpG island and that epigenetic alteration of the island in the promoter region was critical for MGMT expression.
Involvement of methyl-CpG binding proteins in MGMT silencing
To assess whether MBD proteins are involved in MGMT silencing, we examined expression of MBD proteins in A549 and LU65 cells by Immunoblot. MeCP2, MBD1, MBD2a, MBD2b, and MBD3 were (Figure 5a) . Expression of MeCP2, MBD1, and MBD2a was the same between the two lines, however, that of MBD2b and MBD3 was biased. ChIP assay showed that MeCP2 tended to bind to the methylated MGMT CpG island in LU65 (P ¼ 0.027 at R1, P ¼ 0.09 at R2, P ¼ 0.061 at R3); however, there was no difference of MBD1 binding between the two lines (Figure 5b ). Although we tried ChIP assay with antibodies for MBD2a and MBD3, no reproducible result was obtained, indicating that at least one MBD protein, MeCP2, is involved in MGMT silencing with hypermethylation of CpGs and H3K9. 0 UHMR, corresponding to the transcription factor-binding region including minimal promoter, was shown to be hypomethylated in about half the cell lines, but hypermethylated in others, with no apparent correlation between level of methylation and gene expression. Our luciferase assay confirmed previous results obtained by reporter assay with various deletions, in which deletion of a region corresponding to UHMR and DHMR showed 90 and 98% reduction of transcriptional activity, respectively (Harris et al., 1991 (Harris et al., , 1994 ; Nakabeppu et al., unpublished data). Thus, we thought that transcriptional silencing due to hypermethylation was caused by the inaccessibility of transcription factor binding. Since there are two SP1 sites in 5 0 UHMR and MEBP binds to the enhancer (Harris et al., 1994; Chen et al., 1997) , it is conceivable that hypermethylation of 5 0 UHMR and the enhancer might induce the regions to prevent binding of those proteins and to lead to gene silencing.
MGMT expression was also associated with chromatin structure of the transcription factor-binding region, which was a region around the minimal promoter within 3 0 UHMR, including six SP1 sites (Costello et al., 1994b; Pieper et al., 1996; Patel et al., 1997; Watts et al., 1997) . In MGMT-negative cells, the transcription factor-binding region was condensed chromatin and was inaccessible to interactions with nucleases (restriction endonucleases, DNaseI, and MNase), regardless of the CpG methylation status of the region itself. In this case, both outside sequences of the region showed CpG hypermethylation. On the other hand, in MGMTpositive cells, the region might be open chromatin or nucleosome-free and both the outside sequences were hypomethylated (Pieper et al., 1996; Patel et al., 1997) . The result of ChIP assays with antibody 5.1.1 revealed condensed chromatin throughout the CpG island in silent transcription. ChIP assays also showed a low level of H3Ac, H4Ac, and H3meK4 at R2, which is in the transcription factor-binding region, in A549. These low levels were probably due to a very small number of nucleosomes at the transcription factor-binding region in the active transcription state. This less-nucleosomal chromatin would cause less immunoprecipitation during ChIP preparation, resulting in poor PCR amplification (Figure 4b and c) .
It is believed that methylated DNA sequences are bound by MBD proteins, such as MeCP2 and MBD2, and make complexes including histone deacetylase (HDAC) (Mukai and Sekiguchi, 2002) . MeCP2 can bind to the methylated CpG island, and its binding is associated with deacetylation at the p14/p16 locus (Nguyen et al., 2001) . Fuks et al. (2003) reported that MeCP2 associated with methyltransferase activity on H3K9 in vivo, although the identity of the H3K9 methyltransferase was still unknown. Swi6, a homologue of heterochromatin protein HP1, was required for spreading in cis and maintenance of H3K9 methylation at the mating-type region in fission yeast (Nakayama et al., 2001; Hall et al., 2002) , and the cooperative spreading of noncoding Xist RNA and H3K9 methylation via HP1-like factors was proposed for X inactivation in mammals (Heard et al., 2001) . We showed that MeCP2, rather than MBD1, was associated with CpG and H3K9 methylation in LU65. mRNA of histone methyltransferases, SUV39H1 and G9a, was abundantly expressed in both lines (data not shown). . MeCP2 tended to bind to methylated MGMT CpG island in LU65 (P ¼ 0.027 at R1, P ¼ 0.09 at R2, P ¼ 0.061 at R3). There is no statistical difference of MBD1 between the two lines DNA methylation and histone modifications at MGMT gene T Nakagawachi et al Furthermore, highly methylated H3K9 at the transcription factor-binding region with CpG hypomethylation in LK2 was found (Zhao et al., unpublished data) .
Therefore, we propose a scenario for MGMT gene silencing that depends on the epigenetic state in cancer. At the active transcriptional state, DNA sequences in the whole CpG island are unmethylated. H3 and H4, both outside the transcription factor-binding region, are highly acetylated, forming open chromatin, and transcription factor(s) binds to the region, leading to less-nucleosome structure. At the silencing state, 3 0 , especially enhancer, and/or 5 0 sequences outside the transcription factor-binding region, are firstly methylated. Then MeCP2 binds to the methylated CpGs and recruits HDAC(s) to deacetylate lysine residues. MeCP2 also mediates methylation on H3K9 through histone methyltransferase activity and condenses the chromatin. Condensed chromatin propagates into the transcription factor-binding region via HP1-like factors, then transcription factor(s) and MEBP are inaccessible to the appropriate target sequences, and finally gene transcription is shut off. ChIP assay on HeLa showed basically the same histone modification pattern as A549. In addition, A549 and LU65 diminished the luciferase activity when construct B was transfected (data not shown). Furthermore, HeLa expresses all MBD proteins (data not shown). The evidence indicated that the mechanism of MGMT silencing is analogous between HeLa and lung cancer cell lines. However, since a number of studies have shown that the mechanism of expression by CpG methylation is different depending on promoters and cell types (Ng et al., 1999; Ballestar and Wolffe, 2001; Magdinier and Wolffe, 2001; Roder et al., 2002) , we could not rule out the involvement of other MBD proteins, especially MBD2, in MGMT silencing.
Some MGMT(À) cell lines, such as SaOS2 and YES3, in which DNA methylation status was less extensive, showed the same expression level as heavily methylated cell lines. The evidence suggested a DNA methylationindependent mechanism leading to the alteration of chromatin configuration and gene silencing. Indeed, Bachman et al. (2003) have recently reported that histone modification associated with silencing of a tumor suppressor gene could occur independently of DNA methylation. Although in Neurospora crassa and Arabidopsis thaliana, the presence of H3meK9 was essential for all or a subset of DNA methylation (Tamaru and Selker, 2001; Jackson et al., 2002) , the mechanism may be more intricate in mammalian cells. Further studies must be conducted to clarify a hierarchy of DNA methylation and H3K9 methylation on chromatin condensation and gene silencing.
Materials and methods
Cell lines
A total of 131 human cancer cell lines were screened for MGMT expression. Cancer cell lines used for further analyses are shown in Table 1 . FRO, HeLaMR, KYSE140, KYSE510, TE9, and U251 were grown in Dulbecco's modified Eagle's medium with 10% FCS. A549, CRL1500, DBTRG05MG, HeLa, HeLaTG, Ho1u1, LK2, LU65, SaOS2, SCCH26, Shimura, YES1, YES3, 5637, and normal human lymphoblastoid cells were grown in RPMI-1640 with 10% FCS. MDAMB435S was grown in Leibovitz's L-15 with 15% FCS. SW48 and SW620 were grown in Leibovitz's L-15 with 10% FCS and 2 mM of L-glutamine. HeLaS3 and IMR32 were grown in minimal essential medium with 10% FCS, 1 mM of sodium pyruvate, and 0.1 mM of nonessential amino acid. Growing cells with 70% confluence were harvested for analyses.
RT-PCR
The total RNAs were extracted with ISOGEN (NIPPON-GENE). In all, 500 ng of total RNA was treated with RNasefree DNaseI (Roche) and reverse-transcribed with ReverTra Ace reverse transcriptase (TOYOBO). To screen the expression of MGMT, RT-PCR with 38 cycles was performed, using an exon connection primer pair (sense primer in exon 2, 5 0 -GCTGGAGCTGTCTGGTTGTG-3 0 ; antisense primer in exon 4, 5 0 -GGGCTGCTAATTGCTGGTAA-3 0 ) and PCR product was detected by ethidium bromide staining. After screening, quantitative real-time RT-PCR was performed in triplicate with the FastStart DNA Master CYBR Green I on LightCycler TM system (Roche) acceding to the manufacturer's protocol. The expression of MGMT was normalized with that of b-actin, as described previously (Satoh et al., 2003) . A lymphoblastoid cell line derived from normal human peripheral lymphocytes was used as a standard.
Bisulfite modification and sequencing analysis
Genomic DNAs were extracted with a protocol described by Miller et al. (1988) . In total, 1 mg of genomic DNA was modified by the urea/bisulfite method (Paulin et al., 1998) . The whole CpG island in the MGMT promoter region was amplified by nested PCR. Primer sequences and PCR conditions were described previously ( Figure 1a ) (Matsukura et al., 2003) . The nested PCR products were cloned, and at least 10 clones for each sample were sequenced. It was previously confirmed that the nested PCR could accurately reflect the methylation status of genomic DNA (Matsukura et al., 2003) .
Plasmid constructions and luciferase reporter gene assay PCR-amplified product containing the whole CpG island in the MGMT promoter region was cloned into PiCagene Basic Vector (PBV, TOYO INKI MFG. Co. Ltd) at MluI and XhoI sites (construct A in Figure 2 ). To generate construct B, the insert DNA was digested with PstI and methylated by SssI methylase (New England Biolabs), then cloned into PBV. Methylated or unmethylated fragments, UHMR and DHMR, generated by XbaI digestion, were ligated with an appropriate combination to generate constructs C, D, and E. Each ligated fragment was then ligated to PBV. Since the ligation mixture included unligated fragments, we confirmed that luciferase activity of the fragment mixture, which contained unligated UHMR fragment and XhoI-PstI vector DNA, was at a significantly low level, the same as mock (data not shown). Thus, we concluded that the ligation mixture could be directly used for the luciferase assay. Each linearized construct was independently transfected into HeLa cells expressing MGMT constitutively. PiCagene Seapansy control vector (TOYO INKI Mfg. Co. Ltd) was cotransfected as internal control.
After transfection followed by incubation for 48 h, luciferase activity was measured with the Dual Luciferase System Assay Kit (TOYO INKI Mfg. Co. Ltd), according to the manufacturer's instructions. This assay was performed independently at least three times for each construct.
Generation of anti-histone H3 dimethyl K9 monoclonal antibody
Peptides for histone N-tail were synthesized; H3-m2K4
. H3-m2K9 peptide coupled with Keyhole limpet hemocyanin (Pierce) was used to immunize mice. Serum titers were monitored by immunoblot using GST-H3 (1-57) in vitro methylated by recombinant GST-G9a-C (Tachibana et al., 2001) . After multiple injections, spleens were harvested, and splenic lymphocytes were isolated and fused to myeloma cell line NS-1. Clonal populations of fusion cells were screened for antibody production by enzyme-linked immunosorbent assay, and productive cell wells were cloned to monoclonal lines by serial dilutional screening (Urano et al., 1993) . The 5.1.1 monoclonal antibody was used for the present studies. Highly concentrated antibody was obtained from murine ascites after intraperitoneal injection of hybridoma cells. For antibody-peptide binding analysis, surface plasmon resonance measurements were performed using a BIAcore 3000 instrument (Biacore) equipped with CM5 sensor chips. All analyses of interactions between peptides and antiH3meK9 monoclonal antibody 5.1.1 were performed in 10 mM HEPES, pH 7.4, 0.15 M NaCl, 1 mM CaCl 2 , 0.005% surfactant 20 (v/v), which was used also as running buffer.
ChIP assays
We used six kinds of antibodies for ChIP: antiacetylated histone H3, antiacetylated histone H4, antidimethylated histone H3K4 (Upstate Biotechnology), monoclonal antibody 5.1.1 against dimethylated histone H3K9, anti-MecP2 (Kudo, 1998) , and anti-MDB1 (Abcam). Chromatin was prepared from 1.0 Â 10 6 cells and sonicated to average size B0.5 kb, then immunoprecipitated with each antibody. Protein A sepharose beads were used to collect the immunoprecipitated complex with all antibodies except protein G beads for antibody 5.1.1. DNA recovered from immunoprecipitated complex was subjected to PCR. Primers for ChIP-PCR were designed to cover the CpG island ( Figure 1a) ; Ch-F1 (5 0 -TGGACGG-CATCGCCCACCAC-3 0 ) and Ch-R1 (5 0 -TCCGCCTGAGGC TCTGTGCC-3 0 ) for region 1, Ch-F2 (5 0 -TGGACGGCATCG CCCACCAC-3 0 ) and Ch-R2 (5 0 -GGGGCCGAGGGGCACG GGGA-3 0 ) for region 2, Ch-F3 (5 0 -GCCCCGGATATGCTG GGACA-3 0 ) and Ch-R3 (5 0 -GGGCAACACCTGGGAGG-CAC-3 0 ) for region 3. Primers for upstream and downstream of CpG island: Ch-F4 (5 0 -AGTAACAGGCTGTAAGTGGC-3 0 ) and Ch-R4 (5 0 -ATGTGGAAGGACAGATGAAA-3 0 ) for region 4, Ch-F5 (5 0 -AAATCAGAGAAGACACATAAAC-CATC-3 0 ) and Ch-R5 (5 0 -CTGCACAGCTCAAACCTCCT-3 0 ) for region 5. To ensure quantification of PCR amplification, each reaction was initially setup at various amplification cycle numbers, and a logarithmic amplification phase was detected. We determined 31 cycles for each region as the final PCR conditions. PCR products were quantified with NIH Image 1.62, and fold enrichment in each immunoprecipitation was determined by the ratio-to-input DNA (total chromatin). ChIP was performed in triplicate for each cell line, and PCR for each ChIP was performed in at least duplicate.
Immunoblotting
A539 and LU65 cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.25% Na-deoxycholate, 1 mM Na 3 VO 4 , 1mM NaF), including protease inhibitors. Equal amounts of proteins (20-100 mg) were size fractionated by 10% SDS-PAGE and transferred onto PVDF membrane. Membranes were hybridized with antibodies against MeCP2 (Kudo, 1998) , MBD1 (Abcam), and MBD2/3 (Upstate Biotechnology). The proteins were detected with the ECL plus Western blotting detection system (Amersham Biosciences).
